Cargando…

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon

BACKGROUND: Interferon is approved for adjuvant treatment of patients with stage IIB/III melanoma. The identification of predictive markers that would permit selection of patients would be beneficial. Specific human leukocyte antigen (HLA) class I and II antigens have previously shown an association...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogas, Helen, Kirkwood, John M, Falk, Christine S, Dafni, Urania, Sondak, Vernon K, Tsoutsos, Dimosthenis, Stratigos, Alexandros, Markopoulos, Christos, Pectasides, Dimitrios, Spyropoulou-Vlachou, Maria
Formato:	Texto
Lenguaje:	English
Publicado:	Wiley Subscription Services, Inc., A Wiley Company 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970916/ https://www.ncbi.nlm.nih.gov/pubmed/20549830 http://dx.doi.org/10.1002/cncr.25211

Ejemplares similares

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
por: Gogas, Helen, et al.
Publicado: (2010)

A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon
por: Pancoska, Petr, et al.
Publicado: (2014)

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, H, et al.
Publicado: (2002)

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon
por: Wang, Ena, et al.
Publicado: (2012)

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy
por: Markopoulos, Christos, et al.
Publicado: (2009)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial
por: Markopoulos, Christos, et al.
Publicado: (2012)

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
por: Markopoulos, Christos, et al.
Publicado: (2010)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

Abstract: Breast Reduction with Triple Blood Nourishing of the Nipple-Areola Complex: A Novel Concept of the Transverse Bi-Pedicle Reduction Mammaplasty Based on Wuringer’s Septum
por: Kyriopoulos, Eugenia Jenny, et al.
Publicado: (2018)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials
por: Malczewski, Agnieszka, et al.
Publicado: (2015)

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
por: Markopoulos, Christos
Publicado: (2010)

LEUKOCYTES AND INTERFERON IN THE HOST RESPONSE TO VIRAL INFECTIONS : I. MOUSE LEUKOCYTES AND LEUKOCYTE-PRODUCED INTERFERON IN VACCINIA VIRUS INFECTION IN VITRO
por: Glasgow, Lowell A.
Publicado: (1965)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients
por: Karakitsos, Dimitrios, et al.
Publicado: (2006)

The Role of Myositis-Specific and Myositis-Associated Autoantibodies and the Activation of Type I Interferon Pathway in the Generation of Clinical Phenotypes of Inflammatory Myopathies
por: Skarlis, Charalampos, et al.
Publicado: (2023)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
por: Daud, A. I., et al.
Publicado: (2010)

Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon?: Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1
por: Sondak, Vernon K.
Publicado: (2009)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Glycogen-rich clear cell carcinoma of the breast
por: Markopoulos, Christos, et al.
Publicado: (2008)

INTERFERON PRODUCTION BY MOUSE LEUKOCYTES IN VITRO AND IN VIVO
por: Glasgow, Lowell A., et al.
Publicado: (1963)

Interferons as cytokines regulating leukocyte functions in vivo
por: Virelizier, J.-L.
Publicado: (1985)

Enrichment of coronavirus-induced interferon-producing blood leukocytes increases the interferon yield per cell: A study with pig leukocytes
por: Nowacki, W., et al.
Publicado: (1993)

Hemolytic uremic syndrome following the infusion of oxaliplatin: case report
por: Dahabreh, Issa, et al.
Publicado: (2006)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Papaxoinis, George, et al.
Publicado: (2015)

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
por: Eljilany, Islam, et al.
Publicado: (2023)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Interferon induction in porcine leukocytes with transmissible gastroenteritis virus
por: Naidoo, D., et al.
Publicado: (1992)

Interferon production by leukocytes in children with otitis media with effusion
por: Pitkäranta, Anne, et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_3ucvk80cedog4g7g1t41opembu